In force Publication date 30 Jul 19
Pharmacokinetics of inhaled salmeterol alone or in combination with fluticasone and investigation of the role of CYP3A4 and P-gp polymorphisms
Resource description
Project Title: Pharmacokinetics of inhaled salmeterol alone or in combination with fluticasone and investigation of the role of CYP3A4 and P-gp polymorphisms
Researchers: Michael Petrou (University of Nicosia, Nicosia, Cyprus; Cyprus Anti-Doping Authority, Cyprus) and Constantinos Pistos (University of Pennsylvania, USA)
Year accepted: 2012
Summary: The main aim of the present study was to contribute to the development of a urinary threshold level to allow anti-doping organisations to differentiate between the permitted therapeutic use of salmeterol and its misuse in sport.